Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)-Reference-Cited by-同舟云学术

Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)

Published:2023-06 Issue:6 Volume:12 Page:1320-1327
ISSN:2218-6751
Container-title:Translational Lung Cancer Research
language:
Short-container-title:Transl Lung Cancer Res

Author:

Araki Taisuke,Kanda Shintaro,Komatsu Masamichi,Sonehara Kei,Tateishi Kazunari,Takada Munetake,Kato Akane,Yamamoto Manabu,Nishie Kenichi,Hama Mineyuki,Agatsuma Toshihiko,Kakizaki Yumiko,Yoshiike Fumiaki,Matsuo Akemi,Chiaki Tomoshige,Samizo Kanae,Takagi Yoshiko,Yamaura Maki,Hanaoka Masayuki,Koizumi Tomonobu

Publisher

AME Publishing Company

Subject

Oncology

Link

https://tlcr.amegroups.com/article/download/76016/pdf

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non-Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?;CLIN LUNG CANCER;2024

2. Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?;Clinical Lung Cancer;2024-09

3. EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis;Journal of Personalized Medicine;2024-07-15

4. Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study;Biomedicines;2024-06-25

5. EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study;Respiratory Investigation;2024-03